PT-141 in Australia: legal status and listed suppliers

Legal status in Australia

Not an approved medicine. Bremelanotide is not listed by name in the Poisons Standard (June 2026); melanotan II, a related melanocortin peptide, is Schedule 4. No ARTG registration was found.

As understood at 2026-09-22. Verify with the TGA.

What PT-141 is

PT-141, or bremelanotide, is a synthetic peptide that activates melanocortin receptors, developed out of research on analogues of alpha-melanocyte-stimulating hormone. It is an approved medicine in the United States, sold as Vyleesi, for one specific indication in women. Its earlier development as a nasal spray for erectile dysfunction in men was not the route that reached approval.

Full PT-141 page: targets and research →

Listed suppliers in Australia

5 of the 10 suppliers we list in Australia list PT-141. Listed, not endorsed: each row is the supplier’s own stated terms.

Au Peptide Labs Australia For laboratory research use only. Not for human consumption. Aussie Peptides Australia Research use only. Statements have not been evaluated by the TGA. We do not ship internationally at this time. Australian Peptide Site Australia Intended for laboratory and scientific research use only. Next Gen Peptides Australia Not for human consumption. Synapse Peptides Australia Australia All products are supplied strictly for research purposes only and are not intended for human or veterinary use.

Clinical Research

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D, et al. (2019). Obstetrics & Gynecology. human 1,267 premenopausal women with hypoactive sexual desire disorder across two identical phase 3 trials (RECONNECT), randomised, double-blind, placebo-controlled, 24 weeks

Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial

Clayton AH, Althof SE, Kingsberg S, et al. (2016). Women's Health. human 327 premenopausal women with female sexual dysfunction (efficacy population), randomised to placebo or one of three bremelanotide groups, 12 weeks

Safety Profile of Bremelanotide Across the Clinical Development Program

Clayton AH, Kingsberg SA, Portman D, et al. (2022). Journal of Women's Health. review n/a (pooled safety review of 43 completed studies, about 3,500 participants, phases 1 to 3)

Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study

Safarinejad MR, Hosseini SY (2008). Journal of Urology. human 342 men aged 28 to 59 with erectile dysfunction not responding to sildenafil, randomised to intranasal bremelanotide or placebo